NC-531 (Neurochem).
NC-531 is a sulfated glycosaminoglycan mimetic that inhibits amyloid plaque formation, and is under development by Neurochem for the potential treatment of Alzheimer's disease. Phase I clinical trials of NC-531 were ongoing in November 1999, and by October 2002 phase II trials were underway.
In Silico Biosciences, 686 Westwind Drive, Berwyn, PA 19312, USA. Hugo-Geerts@in-Silico-Biosciences.com
Hugo
H
Geerts
D000544:Alzheimer Disease / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D011134:Polysaccharides / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D016229:Amyloid beta-Peptides; D011134:Polysaccharides; C486237:alzhemed